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ABSTRACT
Nuclear factor 90 (NF90) is a double-stranded
RNA-binding protein implicated in multiple cellular
functions, but with few identified RNA partners.
Using in vivo cross-linking followed by immuno-
precipitation, we discovered a family of small
NF90-associated RNAs (snaR). These highly struc-
tured non-coding RNAs of »117 nucleotides are
expressed in immortalized human cell lines of
diverse lineages. In human tissues, they are abun-
dant in testis, with minor distribution in brain,
placenta and some other organs. Two snaR subsets
were isolated from human 293 cells, and additional
species were found by bioinformatic analysis. Their
genes often occur in multiple copies arranged in two
inverted regions of tandem repeats on chromosome
19. snaR-A is transcribed by RNA polymerase III
from an intragenic promoter, turns over rapidly,
and shares sequence identity with Alu RNA and
two potential piRNAs. It interacts with NF90’s
double-stranded RNA-binding motifs. snaR ortho-
logs are present in chimpanzee but not other
mammals, and include genes located in the pro-
moter of two chorionic gonadotropin hormone
genes. snaRs appear to have undergone acceler-
ated evolution and differential expansion in the
great apes.
INTRODUCTION
Proteins in the nuclear factor 90 (NF90) family of double-
stranded RNA-binding proteins participate in many
aspects of vertebrate RNA metabolism [reviewed in (1)]
and have been implicated in development (2,3), the cell
cycle (4) and virus infection (5,6). The two most
prominent protein isoforms are NF90 and NF110 (7,8).
NF90 is also known as DRBP76 (9) and NFAR1 (10), and
NF110 is synonymous with ILF3 (11), NFAR2 (10)
and TCP110 (12). Both exist in complexes with a
distinct protein, NF45 (D. Guan et al., manuscript in
preparation; 13).
Proteins in the NF90 family possess two double-
stranded RNA binding motifs (dsRBMs) (14) as well as
RGG (9) and GQSY (1) nucleic acid binding motifs.
Through in vitro reconstitution experiments, the proteins
have been found to interact with coding and non-coding
RNAs of cellular (2,3,15–18) and viral origin (5,6,19).
Most of these RNA species are not abundant in cells, yet
our earlier work demonstrated that the dsRBMs of NF90
and NF110 are almost completely occupied by cellular
RNA throughout the cell cycle (20). We, therefore, sought
to identify the predominant in vivo binding partners of
NF90 by cloning the RNA species that were cross-linked
to NF90 in live 293 cells using a rigorous and highly
speciﬁc protocol (21). By this means we detected a hitherto
unreported RNA family that forms complexes with NF90
protein and is designated snaR (small NF90-associated
RNA).
This novel RNA family contains three distinct but
related subsets that are encoded by tandemly repeated
genes in two segments of human chromosome 19, as well
as additional gene copies two of which are adjacent to
genes encoding the b chain of chorionic gonadotropin.
The snaRs are modern, rapidly evolving, non-coding
RNAs of  117 nucleotides (nt). Their genes are appar-
ently restricted to humans and chimpanzees. snaR-A is
highly structured, relatively unstable and synthesized
by RNA polymerase III (Pol III) from an intragenic
promoter. The snaRs were detected predominantly in
testis among  20 human tissues tested but are
abundant in many immortalized cell lines. Their distribu-
tion, genetic organization and evolutionary relationships
suggest a biological role relevant to the speciation of
great apes.
MATERIALS AND METHODS
GenBank accession numbers
snaR-A #EU035783, snaR-B #EU035784, human and
chimpanzee snaR genes #EU071051-087.
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Human 293 cell sublines expressing NF90a and NF90b
(21) were maintained in DMEM (Sigma) supplemented
with 8% fetal bovine serum (Sigma) and 100mg/ml
Geneticin (Invitrogen).
Cross-linking, immunoprecipitation, 3’-end-labeling
andRT-PCR
Procedures and recipes are detailed in (21). 293 cell
sublines were blocked with 0.1mg/ml cycloheximide then
washed in phosphate-buﬀered saline (PBS, Sigma) with
0.1mg/ml cycloheximide and 7mMMgCl2. Cells were
incubated in PBS with 7mMMgCl2 and 0.5% formalde-
hyde for 10min at 258C before the addition of glycine
(pH 7, 0.25M ﬁnal) and a further incubation of 5min.
Cells were harvested then lysed on ice for 5min in RIPA
buﬀer. Lysate was pre-cleared with Protein A-Sepharose
(Amersham Biosciences) for 1h at 48C, centrifuged then
incubated with anti-Omni-probe antibody (Santa Cruz
Biotech.)-Protein A-Sepharose complex for 3h at 48C.
Immunoprecipitates were washed ﬁve times, 10min each
at 258C, in Harsh RIPA buﬀer. Immunoprecipitates were
incubated in Cross-Link Reversal buﬀer at 708C for
45min and RNA isolated by Trizol extraction
(Invitrogen). RNA was precipitated with 1 volume
isopropanol in the presence of 1M ammonium acetate
and glycogen and the pellet washed in 75% ethanol,
air-dried and re-suspended in water.
Isolated RNA was 30-radiolabeled by ligation of
[50-a-
32P]-cytidine-30,50-bisphosphate, catalyzed by T4
RNA ligase (New England Biolabs) for 2h on ice.
Immunoprecipitated RNA was incubated with DNase
I (Ampliﬁcation Grade, Invitrogen). A ‘lock-dock’
oligo(dT) primer (0.1mM ﬁnal) was annealed to RNA by
heating at 708C for 10min. Reverse transcription was
performed at 428C for 50min using SuperScript II Reverse
Transcriptase (Invitrogen). The reaction was terminated
at 708C for 15min and RNA was digested with RNase
(15U/ml RNase T1, 4U/ml RNase H) for 30min at 378C.
cDNA was twice puriﬁed through a QIAquick desalting
column (Qiagen), heated at 948C for 2min in Tailing
buﬀer then incubated with terminal deoxynucleotidyl
transferase (New England BioLabs) for 10min at 378C.
The reaction was terminated at 658C for 10min. cDNA
was ampliﬁed over 30 cycles with an annealing tempera-
ture of 638C, using a reverse primer, Abridged Anchor
primer (Invitrogen) and SuperTaq polymerase (Ambion).
Plasmid constructs
GST fusion plasmids pGEX-6P-3-NF90a and -NF90b
were subcloned from pcDNA3.1-NF90a and -NF90b (8)
into pGEX-6P-3 vector (Amersham Biosciences) after
EcoRI digestion. GST-NF90c was expressed from pGST-
NF90 (22). pGEX-6P-3-A458P,A588P, was generated by
digesting pcDNA3.1-NF110b(A458P,A588P) (23) with
AvrII and HindIII, then inserting the gel puriﬁed fragment
into similarly digested pGEX-6P-3-NF90b. To create
pGEX4T-3-NF45, NF45 was PCR ampliﬁed from
pcDNA3-NF45 (24) using primers F45 (50-CGACAGAA
TTCCATGAGGGGTGACAGAGG-30) and R45 (50-CC
TGTGCGGCCGCTTCACTCCTGAGTTTCCATGC-30).
The PCR product was digested with EcoRI and NotI
and ligated into similarly digested pGEX4T-3 vector
(Amersham Biosciences).
To remove extraneous 30 and 50 RT-PCR priming
sites from snaR-A sequence, pCR2.1-Clone 3 was PCR
ampliﬁed using primers F-A (50-GAGGTCTAG
ATTGGAGCCATTGTGGCTC-30) and R-A (50-GAGG
AAGCTTCCGACCCATGTGGACCA-30). The PCR
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Figure 1. snaRs are highly structured NF90-associated RNAs.
(A) RNA immunoprecipitated from cell lines with anti-omni antibody
was 30-end labeled and resolved in a 5% acrylamide/7M urea gel (21).
Cell lines contained omni-tagged NF90a or NF90b (lanes 2 and 3) or
empty vector (lane 1). Note that the cell extracts contained more
NF90b than NF90a. (B) The most stable snaR-A and -B structures
predicted by MFOLD (27). Base-pairing is represented by dots. snaR-B
bases altered or deleted (open triangle) in snaR-C are circled.
(C) Northern blot of supernatant  10
 3 (Sup) and immunoprecipitated
(IP) RNA from the cell lines probed with Probe-A (Figure S2A).
30-pCp-labeled RNA precipitated with NF90a served as a marker (M).
(D) RNA immunoprecipitated with NF90b was 30-end labeled, digested
with RNase H in the presence of sense (S) or antisense (AS)
oligonucleotides corresponding to snaR (probe H, Figure 2B) or 5S
rRNA and resolved in a 5% acrylamide/7M urea gel. Asterisk marks
snaR-A RNase H digestion product, bromophenol blue (bpb) migra-
tion is denoted. (E) In vitro binding assay of T7 RNA polymerase
transcribed snaR-A to equal amounts of GST fusion proteins
(Figure S1) in the presence of 2000-fold molar excess yeast tRNA.
NF90b [A458P,A588P] mutant is denoted by ‘GST-Mut’ and 20%
input was loaded.
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into similarly digested pCRII vector (Invitrogen), to create
pCRII-snaR-A. T7 run-oﬀ transcription from linearized
pCRII-snaR-A produces snaR-A with 21 extraneous
50-ﬂanking nucleotides. To utilize transcribed snaR-A
as an accurate size marker, snaR-A was PCR ampliﬁed
from the pCRII-snaR-A construct using primers F-A2
(50-GGCAAAGCTTTAAAATCCTTTTTTCCGACCCA
TGTGGACCAGG-30) and R-A2 (50-GGCAGGATCC
TAATACGACTCACTATAGCCGGAGCCATTGTGG
CTCAGG-30). These primers place the snaR-A gene at
position +2 and introduce a DraI restriction site after
four terminal uridines. The PCR product was digested
with BamHI and HindIII and inserted into similarly
digested pUC18 vector (Invitrogen).
To construct pR1-R3, fragments of chromosome
19 encompassing a snaR-A gene (55299144, Table 1)
were PCR ampliﬁed from genomic DNA using primers F1
(50-GGCGTCCTCCCTTTATGTTTTGTCG-30) and
either R1 (50-GGAGCCATTGTGGCTCAGGC-30),
R2 (50-CTGAACTCTCAGATACAGTTCCCC-30)o r
R3 (50-CACTGCGCCAGCCTTGTTTCTCG-30), then
inserted via TOPO TA Cloning technology (Invitrogen)
into pCR2.1 vector (Invitrogen).
RNase H digestion
Immunoprecipitated RNA ( 25% isolated) was 30-end
labeled as described above. Labeled RNA (13.4ml ﬁnal)
was incubated at 708C for 10min in the presence of
100mM oligonucleotide speciﬁc for snaR (sense, 50-GGG
CACGAGTTCGAGGCC-30 or antisense, 50-GGCCTCG
AACTCGTGCCC-30) or 5S rRNA (sense, 50-AACGCGC
CCGATCTCGTCTGA-30 or antisense, 50-TCAGACGA
GATCGGGCGCGTT-30), then cooled. RNA was incu-
bated with RNase H (5U, New England BioLabs) in
the supplied reaction buﬀer at 308C for 3h. Digestion
was stopped with 16ml2   formamide loading buﬀer
(95% formamide, 10mM Tris-HCl, pH 8, 20mM EDTA)
and heating at 708C for 5min.
GST pull-down assay
GST protein extract was prepared as previously described
(22). Extract was rocked at 48C for 1h with 6ml GSH
snaR-A 
         5’------------------------------------------------------------------------------------------------------>3’ nt. 
Clone12m -CTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone19m -CTGGAGCCATTGTGGCTCAGGCCGGTTGCCCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCAAGGCCAGCCTGGTCCACATGGGTCG- 103 
Clone20m -CTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone12  -TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGAGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone13  TCTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGAGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 105 
Clone15i --TGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 103 
Clone3   -TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone16a -TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone2   -TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone17  -TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone18  -TCGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGCCCAGCCTGGTCCACATGGGTCGG 104 
Clone15  -TCGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone8a  -TGGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 104 
Clone16  -----AGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 100 
Clone1   --AGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 103 
              ************************* ***************************** ****************** ** **********************   
Consensus TTGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGG-AGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG 
 
snaR-B 
 
Clone21m -----AGCCATTGTGGCTCCGGCCGGTTGCGCGGGCCCTCGGACTCTCAGGGTAGGCGAGGGTTCGAGGGCACGAGTTCGAGGCCAACCTGGTCCACATGGGTTG 100 
Clone18a -TTGGAGCCATTGTGGCTCCGGCCGGTTGCGCGGGCCCTCGGACTCTCAGGGTAGGCGAGGGTTCGAGGGCACGAGTTCGAGGCCAACCTGGTCCACATGGGTC- 103 
Clone7m  -ATGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGACCCTCAGGGTAGGCGAGGGTTCGAGGGCACGAGTTCGAGGCCAACCTGGTCCACATGGGTTG 104 
              ************** ************  ********** **********************************************************   
Consensus  TGGAGCCATTGTGGCTCCGGCCGGTTGCGCGGGCCCTCGGACTCTCAGGGTAGGCGAGGGTTCGAGGGCACGAGTTCGAGGCCAACCTGGTCCACATGGGTTG 
snaR-A 19q13.33:55287566:55287678 
5’-CCCGGAGCCATTGTGGCTCAGGCCGGTTGCGCCTGCCCTCGGGCCCTCACGGAGGCGGGGGTTCCAGGGCACGAGTTCGAGGCCAGCCTGGTCCACATGGGTCGG AAAAAAGGATTTTTTTTA-3’ 
 
snaR-B 19q13.33:55328830:55328932 
5’-CCCGGAGCCATTGTGGCTCCGGCCGGTTGCGCGGGCCCTCGGACCCTCAGGGTAGGCGAGGGTTCGAGGGCACGAGTTCGAGGCCAACCTGGTCCACATGGGTTG AAAAAAAAATTTTTTTA-3’ 
piR-36011                                                                                 5 -GGCCAGCCUGGUCCACAUGGGUCGGAA-3   
snaR-A    5’-UUGGAGCCAUUGUGGCUCAGGCCGGUUGCGCCUGCCCUCGGGCCCUCACGGAGGCGGGGGUUCCAGGGCACGAGUUCGAGGCCAGCCUGGUCCACAUGGGUCGGAAAAAAGGAUUUUU-3’  
piR-36189                                                                  5 -GGGCACGAGUUCGAGGCCAGCCUGGUCCAU-3    
A
B
C
Figure 2. snaR RT-PCR clones. (A) Clones of snaR identiﬁed from sequencing of RT-PCR products (21) can be grouped into two subsets.
Homology within each subset is denoted by an asterisk and non-homologous nucleotides are in bold font. Diﬀerences between subsets are denoted by
gray shading. Consensus sequences are given below each set of clones. The majority of clones are derived from asynchronous NF90b cell line extract.
Clones with ‘m’ or ‘a’ appended to their name were immunoprecipitated from NF90b G2/M phase extract or from NF90a extract, respectively.
(B) The genomic sequence of snaR-A and -B. Genomic nucleotides matching consensus sequence are highlighted in yellow, those diﬀering from
consensus sequence are in green. 30-Oligo(A) and oligo(T) tracts are denoted in red and blue, respectively. Dashed line denotes sequence
complementary to probe H, solid line denotes predicted RNase H digestion product. (C) Sequence alignment of snaR-A with two potential piRNAs
(bold). Alu RNA homology is denoted in yellow. Sequence homologous to the PolIII B box motif is underlined.
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Tris, pH 8, 120mM NaCl, 0.5% NP-40, 1mM DTT).
Beads were washed thrice for 2min in 1ml EBCD buﬀer
and 0.075% SDS and twice for 2min in 1ml low salt
buﬀer (50mM Tris, pH 7.6, 50mM NaCl) at 48C with
rocking. A third of the beads were set aside for protein
analysis in a 7.5% SDS/PAGE gel. Beads were washed
twice on ice in 1ml Binding buﬀer (25mM Hepes
KOH, pH 7.4, 0.1M KCl, 10mM MgCl2, 0.1mM
EDTA, 1mM DTT, 10mM PMSF, 0.1mg/ml BSA,
0.1mg/ml tRNA)+0.01% NP-40, then once in 1ml
Binding buﬀer. Radiolabeled snaR-A ( 200fmol) was
incubated with the beads (  12pMol of immobilized GST
protein) in 10ml Binding buﬀer with 1U/ml RNasin at
308C for 5min, then on ice for 25min. Beads were washed
thrice in 1ml modiﬁed Binding buﬀer (with 175mM KCl,
10mg/ml tRNA, 0.01% NP-40) and bound snaR-A was
eluted in 250ml Elution buﬀer (50mM Tris pH 7.4,
150mM NaCl, 0.05% NP-40, 50mg/ml tRNA, 0.5%
SDS). RNA was phenol extracted (200ml) and precipitated
in EtOH in the presence of 20mg/ml glycogen and 1M
ammonium acetate.
Northern blots
Apart from fetal kidney RNA (Clontech), all human tissue
RNA was purchased from Ambion. RNA was resolved
in polyacrylamide/7M urea gels and transferred in
0.5  TBE to GeneScreen Plus nylon membrane
(PerkinElmer Life Sciences) by electroblotting.
Membranes were blocked in ULTRAhyb-Oligo hybridi-
zation buﬀer (Ambion) for 1h at 378C, before hybridiza-
tion at 378C for 16h with 50-end labeled oligonucleotide.
Blocking and hybridization of labeled RNA complemen-
tary to clone 3 was carried out at 428C. Membranes were
washed twice in 2  SSC with 0.1% SDS for 10min at
258C. All oligonucleotide probes were 50-end labeled with
32P-g-ATP using T4 polynucleotide kinase (New England
BioLabs) and puriﬁed over Micro Bio-Spin P-30 chroma-
tography columns (Bio-Rad). Oligonucleotides used in
this study: Probe A 50-GACCCATGTGGACCAGGCT
GGCCTCGAACT-30, 5.8S rRNA 50-CGCAAGTGCGT
TCGAAGTGTC-30.
In vitro transcription
Genomic DNA from 293 cells was prepared as previously
described (25). In vitro transcription of pVAII (26),
linearized CMV DNA, and pR1-R3 was performed
using the HeLa Cell Extract Transcription System
(Promega). T7 and SP6 RNA polymerase run-oﬀ tran-
scription from linearized pCRII-snaR-A yielded radiola-
beled sense and antisense snaR-A, respectively.
Table 1. Subsets of human snaR genes
Subset Chrom (Strand)
a Start
b %I D
c 30-Terminus Flanking homology
d
A 19 (+) 53113498 100 A6GGACT8 100:100
A 19 (+) 53118848 100 A6GGAT8 100:100
A 19 (+) 53129250 100 A6GGACT8 100:99
A1 9 (  ) 55287678 100 A6GGAT8 100:100
A1 9 (  ) 55293015 100 A6GGAT8 100:100
A1 9 (  ) 55296080 100 A6GGAT8 100:100
A1 9 (  ) 55299144 100 A6GGAT8 100:100
A1 9 (  ) 55302203 100 A6GGAT8 100:100
A1 9 (  ) 55307557 100 A6GGAT8 100:100
A1 9 (  ) 55312909 100 A6GGAT8 100:100
A1 9 (  ) 55318263 100 A6GGAT8 100:100
A1 9 (  ) 55323591 100 A6GGAT8 100:100
A 19 (+) 53102747 99.1 A6GGACT8 100:100
A 19 (+) 53139991 99.1 A6GGACT8 100:100
B1 9 (  ) 55328933 90.4 A9T7 97.3:96
B1 9 (  ) 55334306 90.4 A9T7 98:96
C 19 (+) 53145365 89.4 A9T7 97.3:95
C 19 (+) 53134610 88.5 A9T8 96.7:96
D1 9 (  ) 55335389 88.5 A8T7 46.7:96
E1 9 (  ) 52025799 87.5 A15T2 42.7:31
C 19 (+) 53108120 87.5 A9T8 97.3:97
C 19 (+) 53123887 87.5 A9T8 96.7:97
C 19 (+) 53150751 87.5 A9T8 97.3:96
F 19 (+) 55800032 86.5 A10T8 94:96
3 3 (+) 192078417 86.5 A8T8 93.3:96
22 (  ) 78035660 86.5 A10T7 94.7:95
G2 19 ( ) 54226855 83.7 A7T7 92:95
G1 19 (+) 54232089 80.8 A14T7 91.3:96
A UCSC BLAT search of the human genome (NCBI Build 36.1) for snaR-A consensus (Figure 2A). ‘Hits’ have  80% sequence identity to snaR-A
consensus and were categorized into three subsets and seven outliers. Search included two 50-terminus cytidines that are present as uridines in the
consensus sequence.
aChromosome (Chrom) and strand polarity is denoted.
b‘Start’ nucleotides are given with respect to the chromosomal numbering system.
c‘% ID’ is a percentage comparison of gene primary sequence to that of snaR-A consensus sequence, as determined by ClustalW alignment.
dPercentage comparison of 50 (150nt upstream) and 30 (100nt downstream) ﬂanking sequence to that of snaR-A, as determined by ClustalW
alignment.
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A novel family ofstructured RNAs
To characterize RNAs bound to NF90 in vivo, stable
293 cell lines expressing epitope-tagged isoforms of NF90,
NF90a and NF90b, were subjected to formaldehyde
cross-linking (21). The a and b isoforms diﬀer only in
the absence or presence of a four amino acid sequence
whose function is unknown (1). The most prominent RNA
species immunoprecipitated with NF90 were  80–120nt
long (Figure 1A), and  12 RNAs were identiﬁed by
cloning and sequencing (21). Several related clones of
 104nt were found, which fell into two subsets: a major
subset, snaR-A, and a minor subset, snaR-B (Figure 2A).
The subsets are  90% identical in sequence. Human
genomic sequences corresponding to snaR-A and snaR-B
had occasional mismatches that are possibly due to
C-to-U editing of the RNA (Figure 2B). In the genome,
the cloned snaR sequences are followed by a run of
adenines that accounts for the cloning of these RNAs by
RT-PCR with an oligo(dT) primer, and then by a run of
thymidines that constitutes a potential PolIII termination
site. Placing the 30 terminus within the oligo-(U) run gives
a length of  117nt, consistent with the RNAs’ gel
mobility.
The snaRs lack an open reading frame and are
predicted to fold into thermodynamically stable hairpin
structures (Figure 1B). The structures illustrated
have calculated G of folding of  56kcal/mol and
>60% G:C base-pairing, but several alternative structures
have similar stability (27). The dynamic secondary
structure prediction program paRNAss (28) predicts that
snaR-A can readily undergo a conformational switch
which might account for mobility shifts seen in higher
percentage acrylamide gels (see subsequently).
snaR isamajor NF90binding partner
A single band was detected when 293 cell RNA was
examined by northern blotting with a DNA oligonucleo-
tide complementary to snaR-A. As expected, this band
was enriched in the NF90 immunoprecipitate (Figure 1C,
lanes 5–7) and co-migrated with the major end-labeled
RNA band that was immunoprecipitated with NF90
(lane 1). To evaluate the amount of snaR-A in this gel
band, NF90-associated RNA was 30-end labeled and
incubated with RNase H in the presence of an oligonu-
cleotide complementary to snaR-A and -B. The labeled
snaR band was completely digested and replaced by the
predicted end-labeled fragment of  35nt (Figure 1D,
lane 4). No digestion resulted from incubation in the
presence of an oligonucleotide with a sequence identical to
that of snaR-A (lane 3). A faint band corresponding to 5S
rRNA was identiﬁed in a similar fashion (lanes 1 and 2).
These results identify snaR-A as one of the principal
RNAs cross-linked to NF90 in vivo. We estimate that
there are  70000 molecules of snaR-A in a 293 cell
(data not shown), compared to  200000 copies of 7SK
RNA (29).
Structured RNAs such as VA RNAII interact with
NF90 via its dsRBMs (5). To determine whether
functional dsRBMs are required for the NF90/snaR
interaction, we examined the ability of NF90 to bind
snaR-A in vitro. In a pulldown assay, radiolabeled snaR-A
bound to GST fusions with all three NF90 isoforms,
NF90a–c, but not to GST itself or GST-NF45
(Figure 1E). Binding was not detected to the NF90b
[A458P,A588P] mutant which contains inactivating
mutations in both of its dsRBMs. Hence, NF90 binds
directly to snaR-A via its dsRBMs, consistent with the
high degree of secondary structure predicted for the RNA.
PolIII transcriptionand rapid turnover ofsnaR-A
Nearly all of the snaR genes contain a 30-terminal oligo
(dT) run that could serve as a PolIII termination signal
(Table 1). They also exhibit homology with the PolIII
B box motif (Figure 2C, see subsequently). To determine
which RNA polymerase transcribes the snaR genes,
we transcribed a chromosomal fragment encompassing a
snaR-A gene in HeLa nuclear extract. snaR-A synthesis
persisted in the presence of 20mg/ml a-amanitin, a
concentration that reduces PolIII activity by  50% but
completely inhibits PolII (30), but was abrogated in the
snaR-A
pVA II
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Figure 3. snaR-A is a rapidly synthesized PolIII transcript. (A) In vitro
transcription of linearized DNA containing the CMV promoter,
adenovirus VA RNAII (pVAII), and snaR-A from pR3 with HeLa
cell nuclear extract in the presence of 0, 20 or 200mg/ml a-amanitin. M:
30-end labeled cytoplasmic RNA. (B) In vitro transcription in HeLa cell
nuclear extract of snaR-A from pR1 and pR2, and by T7 RNA
polymerase from linearized pT7-snaR-A. A schematic of pR1-R3
constructs (boxed) gives upstream sequence (numbered) with respect to
the snaR-A transcriptional start site (bent arrow). (C) Northern blot of
total RNA from HeLa S3 cells after exposure to 1mg/ml actinomycin D
for 15, 30, 60 or 180min or to 100mg/ml cycloheximide (ChX), 10mg/ml
a-amanitin, 10mM DRB or DMSO for 180min. Blot was probed with
Probe-A (upper) and 5S rRNA antisense oligonucleotide (lower).
Nucleic Acids Research, 2007, Vol. 35, No. 18 6253presence of 200mg/ml of the toxin (Figure 3A, lanes 7–9).
The adenovirus-2 VA RNAII gene, which is transcribed by
PolIII, exhibited a similar sensitivity (lanes 4–6), whereas
PolII transcription driven by the CMV immediate-early
promoter was abrogated at 20mg/ml a-amanitin (lanes 2
and 3). snaR-A was also generated by constructs contain-
ing less or no chromosomal sequence upstream of the
snaR-A gene (Figure 3B, lanes 3 and 4). The in vitro
product had the expected RNase H sensitivity (data not
shown) and the same gel mobility as a T7 RNA
polymerase run-oﬀ transcript of full-length snaR-A
(lane 1). We conclude that the snaR-A gene is transcribed
by PolIII from an intragenic promoter.
To determine the stability of snaR-A, we monitored
its disappearance in HeLa cells treated with actinomycin
D to inhibit transcription by all polymerases. Northern
blotting showed that snaR-A decays rapidly, with a
half-life of  15min (Figure 3C). Inhibitors of PolII
transcription and translation had little eﬀect. This short
half-life implies a rapid turnover rate and the active
synthesis of snaR-A in cells.
Restricted snaR expression in human tissues and cell lines
To evaluate the distribution of snaR-A, we probed a
northern blot of total RNA from 19 adult human tissues.
High snaR-A expression was seen exclusively in testis
(Figure 4A, upper panel). Long exposures revealed
weak expression in brain and placenta. Remarkably, no
expression was detected in adult kidney or in human fetal
kidney tissue (not shown) even though snaR was initially
discovered in 293 cells which are adenovirus-transformed
cells derived from human embryonic kidney (31) and
express the RNA at high levels (see below). RNA integrity
and loading were assured by probing for 5.8S rRNA
(lower panel). Furthermore, snaR-A was not detected in
RNA from progenitor or adipocyte-diﬀerentiated
mesenchymal stem cells, or from unstimulated or stimu-
lated peripheral blood mononuclear cells (data not
shown).
Considering the possibility that snaR expression is
elevated in tumor cells, we compared RNA from a testis
tumor with that from normal adjacent testis tissue. On the
contrary, reduced expression was seen in the tumor tissue
compared to normal adjacent tissue (Figure 4A, right
panel). We next examined total RNA from 16 permanent
cell lines to determine whether snaR-A is generally
expressed in immortalized cells. Two major bands,
possibly representing conformers or other snaR species
(see subsequently), were detected in all cell lines tested
except Colo205 where only the faster band was seen
(Figure 4B, upper panel). snaR-A was expressed highly in
293 cells, at intermediate levels in HeLa, HepG2 and some
other lines, and at lower levels in lines such as Jurkat and
Colo205. Thus, snaR-A is tightly controlled in human
tissues, where it is largely restricted to testis, but it is
dysregulated in many virally transformed and tumor-
derived cell lines.
With very long exposures, short RNAs of  26–34nt
were detected in testis and 293 cells (Figure 4C, asterisk).
Database search disclosed the existence in a piRNA
library (32) of two sequences that correspond to snaR-A
(Figure 2C). piRNAs are recently discovered germline-
speciﬁc microRNAs deﬁned as binding to PIWI protein
(33). The RNAs piR-36011 and piR-36189 are 27 and
30nt in length, respectively, and their sequences overlap
(32). Interestingly, piR-36189, and hence snaR-A, contain
homology to a region of Alu RNA which possesses the
consensus sequence of the PolIII B box motif (Figure 2C,
(34)). Although it is not known whether these two
particular RNAs bind to PIWI, we attempted to detect
them in 293 cell, testis and brain RNA. Oligonucleotide
probes complementary to the two piRNAs recognized
intact snaR-A in 293 and testis RNA. The piR-36011
probe and snaR-A probe (Probe A), but not the piR-
36189 probe, gave faint hybridization in the 26–34nt
region (Figure 4C). Another PolIII transcript, adenovirus
VA RNAI, was recently found to be processed by Dicer,
albeit ineﬃciently (35). However, the faint bands detected
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Figure 4. snaR is highly expressed in human testis and cell lines.
(A) Northern blots of total RNA extracted from normal adult human
tissue (left) or testis tumor (Tum) and normal adjacent tissue (NAT,
right), probed with Probe-A (upper) or for 5.8S rRNA (lower). Tissues
tested were (from left): brain, thyroid, thymus, heart, adipose, trachea,
lung, skeletal muscle, esophagus, liver, spleen, small intestine, colon,
prostate, kidney, testes, ovary, cervix and placenta. (B) Northern blot
of cell lines with radiolabeled RNA complementary to full-length
snaR-A (upper) or 5.8S rRNA antisense oligonucleotide (lower).
Asterisks denote residual snaR-A bands. (C) Northern blot of 293
cell, brain and testis RNA, probed with Probe-A or oligonucleotides
speciﬁc for piR-36011 or piR-36189. 30-end labeled cytoplasmic RNA
and MspI-digested pBR322 DNA (M) served as size markers. The blot
was cut into strips before hybridization as shown by dashed lines. The
lower panel was exposed 36-fold longer than the upper panel. Asterisk
marks the low molecular weight snaR-related bands.
6254 Nucleic Acids Research, 2007, Vol. 35, No. 18here are more likely to result from snaR-A degradation,
since they are diﬀuse and lack a 50 terminal uracil believed
to be a hallmark of piRNA processing (36).
Multiple divergent human snaR genes
A bioinformatic search of the human genome identiﬁed
28 snaR genes, including 14 genes for snaR-A and 2 genes
for snaR-B (Table 1), all located on the q-arm of
chromosome 19. In addition, the search revealed a further
subset, snaR-C (5 genes), and 7 snaR genes that defy
classiﬁcation into subsets. Although the snaR-C genes
display slight sequence variations (Figure S2A), this subset
is closely related to snaR-B (95–97% identity; Figure 1B).
The outliers, snaR-D to -G, include 5 unique genes on
chromosome 19 as well as single copies (snaR-2 and -3) on
chromosomes 2 and 3 (Table 1).
Genes in the three snaR subsets are located in two
clusters within chromosomal bands 19q13.32 and
19q13.33 (Figure 5A). The clusters are transcribed in
opposite directions and appear to have arisen from an
inversion of a region of segmental duplication. The cluster
on band 19q13.32 has 5 snaR-A genes interspersed with
the 5 snaR-C genes, while the remaining 9 snaR-A genes
and 2 tandem snaR-B genes are on band 19q13.33. Most
of these snaR genes lie in a 5.3kb tandem repeat,
surrounded by multiple repetitive elements such as
SINEs and LINEs (A.F.A. Smit, R. Hubley and
Figure 5. snaR gene organization and evolution. (A) Two regions of human chromosome 19q13.32-33 containing snaR gene clusters are expanded.
The genomic region containing two chorionic gonadotropin beta polypeptide (CGb and snaR genes is boxed. snaR-A, -B and -C genes, labeled to
indicate their subsets, are represented by red, green and blue bars, respectively. Five outlier genes are represented by black bars. Coding gene exons
are shown as cyan rectangles. The direction of snaR transcription is denoted by arrow heads, and that of protein-coding genes by cyan arrows. SINE
and LINE elements predicted by the UCSC genome browser (49) are shown as vertical gray bars. Distances from one end of the chromosome are in
megabases (M). (B) Alignment of human snaR-A and -B with chimpanzee chromosome 3 snaR consensus. Asterisks indicate nucleotide identity, gray
shading indicates heterogenous nucleotides. (C) Phylogram of human (Hs) and chimpanzee (Pt) snaR, derived from a ClustalW sequence alignment
of genes found from UCSC BLAT searches (50) of snaR-A and -B against the human genome (NCBI Build 36.1) and chimpanzee genome (UCSC
version PanTro2). snaR genes are denoted by species:chromosome:start nucleotide labels. snaR-A, -B and -C subsets are highlighted in red, green
and blue, respectively. (D) Region of chimpanzee chromosome 3 (196510-196523 Kb) showing the snaR cluster.
Nucleic Acids Research, 2007, Vol. 35, No. 18 6255P. Green RepeatMasker at http://repeatmasker.org). Each
repeat contains a large LINE L1 element of  1.5kb which
is deleted in three repeat units on band 19q13.33 that
appear to have been truncated by insertion of a SINE Alu-
Sx element.
Most of the outliers share ﬂanking sequence homology
with the snaR genes in the two clusters (Table 1). The
snaR-D, E and F genes are located at varying distances
outside the two clusters on chromosome 19, while snaR-
G1 and -G2 are located in the 2.1Mb genomic fragment
between the clusters. This region contains many protein-
coding genes. Remarkably, these snaR genes lie within the
promoter region of two genes encoding the b polypeptide
of chorionic gonadotropin (CGb; Figure 5A).
snaR isspecific to hominids
snaR genes are present in chimpanzees (Figure 5B), but
were not found in searches of rhesus macaque or other
mammalian genomes. Despite a comparable genome size,
the chimpanzee has fewer snaR genes (10 instead of 28).
As in humans, 7 of the chimpanzee snaR genes have
expanded in a tandem repeat. However, the repeat diﬀers
from those in humans in size and location ( 1.5kb on
chromosome 3; Figure 5D). The repeated chimpanzee
genes are  94% identical with the solitary human snaR
gene on chromosome 3 (Figure S2B), compared to  88%
identity with human snaR-A and –B (Figure 5B). This
suggests the expansion of an orthologous gene on
chromosome 3 has taken place in chimpanzee but not in
humans.
The relationships of the human and chimpanzee genes
were further illuminated by phylogenetic analysis
(Figure 5C). This conﬁrms that the human and chimpan-
zee genes on chromosome 3 are closely related. Similarly,
the single snaR gene on chimpanzee chromosome 2a is
94% identical with its ortholog on human chromosome
2 (Figure S2B). Furthermore, two genes on chimpanzee
chromosome 19 are orthologous with snaR-G1, a unique
gene on human chromosome 19 (Figure 5C, top branch).
Interestingly, their common ancestry is strengthened by
the conserved position of these snaR genes relative to the
primate-speciﬁc CGb genes (37). snaR-G1 and its closest
chimpanzee ortholog are both located 86nt upstream of
the 50 end of the CGb1 gene, which is transcribed in the
opposite direction (Figure 5A, gray box). snaR-G2
mirrors this localization, being 85nt from the 50 end of
human CGb2, although it has diverged considerably
from snaR-G1 and the chimpanzee genes (Figure 5C).
These observations suggest that the snaR genes
originated after the divergence of the Great Apes from
other primates, and have expanded diﬀerentially, some-
times in tandem repeats, since the divergence between
humans and chimpanzees 5–7 MYA (38).
DISCUSSION
The snaRs are a hitherto unrecognized family of small
structured RNAs that are bound in vivo to NF90. These
RNAs turn over rapidly, display a restricted distribution
in human tissues, and appear to have evolved recently in
primates. Accelerated evolution of the snaR genes is
implicit in their restriction to great apes and their diﬀerent
gene copy numbers, location and sequences between
human and chimpanzee. Apart from intra-subset compar-
isons, snaR genes display a lower degree of homology
within the gene than in their ﬂanking sequence
(Figure S2C). This suggests rapid selection and then
conservation of mutations within the loci, presumably due
to divergent function among paralogs. Another rapidly
evolving gene, HAR1F, which speciﬁes a structured non-
coding RNA similar in size to snaR, was recently
associated with the emergence of essentially human
characteristics including the development of the brain
neocortex (39). Strikingly, like the snaRs, this RNA is
expressed in testis as well as in brain.
NF90 is highly expressed in the testis (10), and at least
three other double-stranded RNA-binding proteins—
spermatid perinuclear RNA-binding protein, protamine
1 mRNA-binding protein, and testis nuclear RNA-
binding protein—play critical roles in mammalian sper-
matogenesis [reviewed in (40,41)]. Further work is
required to elucidate why members of this family of
RNAs bind to NF90 protein. The apical stem-loop
appears to be a common feature of snaRs. The stem,
which is structurally stable due to extensive canonical
Watson–Crick base-pairing, is likely to interact with the
dsRBMs of NF90. On the other hand, the apical loop is
variable in size and sequence and could play a part in
determining the speciﬁc functions or targets of these
RNAs.
With the exception of snaR-D and -E, all human and
chimpanzee snaRs share sequence identity upstream
( 150bp) and downstream ( 100bp) of their genes
(Figure S2C). This implies that the majority of snaRs
have ‘piggy-backed’ on a larger segment of DNA which
has generated segmental duplications in both hominids.
However, snaRs also display features characteristic of
retrotransposons: they have an internal PolIII promoter, a
stable hairpin loop structure, and a 30-oligo(A) tract
followed by an oligo(T) tract (42). Three observations are
consistent with their limited retrotransposition. First,
snaR-E resembles snaR-B (Table 1) but lacks the extended
30 oligo(T) tract (transcription termination site) and
surrounding sequence identity with other snaR genes.
Second, snaR-D, which is most closely related to snaR-A,
shares no 50-ﬂanking sequence with other snaRs. Third,
a MUC18 cDNA clone (drop4.7) has been reported that
contains a non-genic 92bp 30-terminus (43): this sequence
is identical to a slightly truncated version of snaR-C.
Transposons and segmental duplications are thought to
be a rich source of rapid molecular evolution in primates,
giving rise to new gene families often involved in
reproduction and immunity (44). While the functions of
the snaRs remain to be established, there is a strong
association with the reproductive system. In addition to
their predominant expression in testis, the locations of the
snaR genes are suggestive. The genomic region between
the two snaR clusters on 19q13 has the highest gene
density on the chromosome [with  110 known or
predicted genes in 2.1 megabases (Table S1), compared
with an average of  60], and many of these genes are
6256 Nucleic Acids Research, 2007, Vol. 35, No. 18integral to reproduction. Most pertinently, the snaR-G
genes are closely linked to the most recent members of the
beta subunit of chorionic gonadotropin glycoprotein
hormone, where they overlap predicted binding sites for
CGb transcription factors that govern early placental
development and implantation (45). The CGb polypep-
tides evolved in primates and have expanded in the great
apes (37,45). The most recent additions to the family,
CGb1 and CGb2, arose in the common ancestor of
African great apes (45). In addition to the critical role of
CGb in the establishment of pregnancy, its overexpression
is diagnostic for certain testicular cancers (46). Indeed,
overexpression of human CGb in transgenic male mice
leads to defective reproductive organs (47) and fetal
Leydig cell adenomas (48). We speculate that snaRs
modulate the expression of CGb polypeptides and
possibly other genes in between the snaR clusters through
an epigenetic mechanism.
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